OXFORDSHIRE, U.K.--(BUSINESS WIRE)--May 15, 2017--
Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and
marketer of endovascular aortic aneurysm repair products, today
announced that it has enrolled and treated the first patient in its
global registry to evaluate its Altura® Endograft System.
The ALTITUDE registry (ALTura Impact on the Treatment
of Abdominal Aortic Aneurysms Using a Novel D-stent EVAR
Design) is being conducted across a range of UK and international
clinical centers to evaluate the use of the Altura Endograft System in
1,000 patients in typical clinical-use conditions.
ALTITUDE’s Chief investigator, Paul Hayes, M.D., F.R.C.S., Department of
Surgery, University of Cambridge and Addenbrooke’s Hospital, Cambridge,
UK, commented, “This registry will allow the clinical community of AAA
implanters to gain necessary experience with Altura. Given the system’s
ultra-low profile, its repositionability, the elimination of the
contralateral cannulation step and retrograde delivery of the limb
sections, this innovative design promises to facilitate a much simpler,
faster, more predictable and consistent deployment of the endograft. The
launch of this registry confirms Lombard’s confidence in the product and
will allow us to develop a robust dataset about long-term outcomes.”
“I am encouraged by our positive early clinical experience with Altura.
The simplicity of planning, accuracy of deployment and repositionability
could lead to it becoming a workhorse device in the future. The ALTITUDE
registry will provide a real world evaluation of the longer term
outcomes,” said Simon Kreckler, M.D., F.R.C.S., vascular & endovascular
surgeon at Addenbrooke’s Hospital, Cambridge, UK.
About Lombard Medical, Inc.
Lombard Medical, Inc. based in Oxfordshire, U.K. develops, manufactures
and markets an innovative range of minimally invasive abdominal aortic
aneurysm endovascular repair products. For more information, please
This announcement contains forward-looking statements that reflect the
Company’s current expectations regarding future events. These
forward-looking statements generally can be identified by the use of
words or phrases such as “believe,” “expect,” “future,” “anticipate,”
“look forward to,” “intend,” “plan,” “foresee,” “may,” “should,” “will,”
“estimates,” “outlook,” “potential,” “optimistic,” “confidence,”
“continue,” “evolve,” “expand,” “growth” or words and phrases of similar
meaning. Statements that describe objectives, plans or goals also are
forward-looking statements. Forward-looking statements are subject to
risks, management assumptions and uncertainties. Actual results could
differ materially from those projected herein and depend on a number of
factors, including the success of the Company’s research and development
and commercialization strategies, the uncertainties related to the
regulatory process and the acceptance of the Company’s products by
hospitals and other medical professionals, the uncertainty of estimated
revenues and profits, the uncertainty of current domestic and
international economic conditions that could adversely affect the level
of demand for the Company’s products and increased volatility in foreign
exchange rates, the inability to raise additional funds, and the risks,
uncertainties and other factors described under the heading “Risk
Factors” in the Company’s Form 20-F filed with the Securities and
Exchange Commission dated May 1, 2017. Readers are urged to consider
these factors carefully in evaluating the forward-looking statements.
The forward-looking statements included herein are made only as of the
date of this report and the Company undertakes no obligation to update
these statements in the future.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170515005141/en/
Source: Lombard Medical, Inc.
Lombard Medical, Inc.
Kurt Lemvigh, +44 (0)1235 750 800